Association Between Sarcopenic Obesity and Metabolic Syndrome in Adults: A Systematic Review and Meta-Analysis

Author(s): Dima Khadra, Leila Itani, Yomna Chebaro, May Obeid, Miryam Jaber, Reham Ghanem, Agnes Ayton, Dima Kreidieh, Dana E. Masri, Akira Kimura, Hana Tannir, Marwan El Ghoch*.

Journal Name: Current Cardiology Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: In the last two decades, a new phenotype termed Sarcopenic Obesity (SO), in which sarcopenia and obesity coexist, has emerged.

Objective: The aim of this systematic review and meta-analysis was first to assess the prevalence of Metabolic syndrome (Mets) among individuals with and without SO, and second, to determine if SO may increase the relative risk of Mets.

Methods: This study was conducted in adherence to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines and the data were collated by means of metaanalysis and narrative synthesis.

Results: Twelve studies including a total of 11,308 adults with overweight or obesity of both genders met the inclusion criteria and were reviewed, revealing two main findings. First, a similar overall prevalence of Mets in individuals with SO (61.49%; 95% CI: 52.19-70.40) when compared to those without SO (56.74%; 95% CI: 47.32-65.93) was identified. Second, the presence of SO appears not to increase the risk of Mets with respect to those without SO (RR = 1.08, 95% CI: 0.99- 1.17, p = 0.07).

Conclusion: No higher prevalence of Mets among individuals with SO when compared to those with obesity only, nor a significant association between SO and a higher risk of Mets was found.

Keywords: Obesity, overweight, sarcopenia, sarcopenic obesity, metabolic syndrome, reduced lean body mass.

[1]
Choi KM. Sarcopenia and sarcopenic obesity. Korean J Intern Med (Korean Assoc Intern Med) 2016; 31(6): 1054-60.
[http://dx.doi.org/10.3904/kjim.2016.193] [PMID: 27809450]
[2]
Polyzos SA, Margioris AN. Sarcopenic obesity. Hormones (Athens) 2018; 17(3): 321-31.
[http://dx.doi.org/10.1007/s42000-018-0049-x] [PMID: 30014320]
[3]
Bouchonville MF, Villareal DT. Sarcopenic obesity: how do we treat it? Curr Opin Endocrinol Diabetes Obes 2013; 20(5): 412-9.
[http://dx.doi.org/10.1097/01.med.0000433071.11466.7f] [PMID: 23974769]
[4]
Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol Metab (Seoul) 2013; 28(2): 86-9.
[http://dx.doi.org/10.3803/EnM.2013.28.2.86] [PMID: 24396659]
[5]
dos Santos EP, Gadelha AB, Safons MP, Nóbrega OT, Oliveira RJ, Lima RM. Sarcopenia and sarcopenic obesity classifications and cardiometabolic risks in older women. Arch Gerontol Geriatr 2014; 59(1): 56-61.
[http://dx.doi.org/10.1016/j.archger.2014.03.012] [PMID: 24766993]
[6]
Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010; 33(7): 1652-4.
[http://dx.doi.org/10.2337/dc10-0107] [PMID: 20460442]
[7]
Hwang B, Lim JY, Lee J, Choi NK, Ahn YO, Park BJ. Prevalence rate and associated factors of sarcopenic obesity in korean elderly population. J Korean Med Sci 2012; 27(7): 748-55.
[http://dx.doi.org/10.3346/jkms.2012.27.7.748] [PMID: 22787369]
[8]
Visser M, van Venrooij LM, Vulperhorst L, et al. Sarcopenic obesity is associated with adverse clinical outcome after cardiac surgery. Nutr Metab Cardiovasc Dis 2013; 23(6): 511-8.
[http://dx.doi.org/10.1016/j.numecd.2011.12.001] [PMID: 22397879]
[9]
Park SH, Park JH, Song PS, et al. Sarcopenic obesity as an independent risk factor of hypertension. J Am Soc Hypertens 2013; 7(6): 420-5.
[http://dx.doi.org/10.1016/j.jash.2013.06.002] [PMID: 23910010]
[10]
Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care 2008; 11(6): 693-700.
[http://dx.doi.org/10.1097/MCO.0b013e328312c37d] [PMID: 18827572]
[11]
El Ghoch M, Calugi S, Dalle Grave R. Sarcopenic obesity: Definition, health consequences and clinical management. Open Nutr J 2018; 12: 70-3.
[http://dx.doi.org/10.2174/1874288201812010070]
[12]
Baek SJ, Nam GE, Han KD, et al. Sarcopenia and sarcopenic obesity and their association with dyslipidemia in Korean elderly men: the 2008-2010 Korea National Health and Nutrition Examination Survey. J Endocrinol Invest 2014; 37(3): 247-60.
[http://dx.doi.org/10.1007/s40618-013-0011-3] [PMID: 24615361]
[13]
Messier V, Karelis AD, Lavoie ME, et al. Metabolic profile and quality of life in class I sarcopenic overweight and obese postmenopausal women: a MONET study. Appl Physiol Nutr Metab 2009; 34(1): 18-24.
[http://dx.doi.org/10.1139/H08-135] [PMID: 19234581]
[14]
Khadra D, Itani L, Tannir H, Kreidieh D, El Masri D, El Ghoch M. Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis. World J Diabetes 2019; 10(5): 311-23.
[http://dx.doi.org/10.4239/wjd.v10.i5.311] [PMID: 31139318]
[15]
Tannir H, Kreidieh D, Itani L, El Masri D, El Ghoch M. Reduction of resting energy expenditure and sarcopenic obesity in adults with overweight and obesity: A brief report. Curr Diabetes Rev 2019.
[http://dx.doi.org/10.2174/1573399815666191030092138] [PMID: 31663844]
[16]
Gusmao-Sena MH, Curvello-Silva K, Barreto-Medeiros JM, Da-Cunha-Daltro CH. Association between sarcopenic obesity and cardiovascular risk: where are we? Nutr Hosp 2016; 33(5): 592.
[http://dx.doi.org/10.20960/nh.592] [PMID: 27759996]
[17]
Barazzoni R, Bischoff SC, Boirie Y, et al. Sarcopenic obesity: Time to meet the challenge. Clin Nutr 2018; 37(6 Pt A): 1787-93.
[http://dx.doi.org/10.1016/j.clnu.2018.04.018] [PMID: 29857921]
[18]
Barazzoni R, Bischoff S, Boirie Y, et al. Sarcopenic obesity: Time to meet the challenge. Obes Facts 2018; 11(4): 294-305.
[http://dx.doi.org/10.1159/000490361] [PMID: 30016792]
[19]
Sénéchal M, Dionne IJ, Brochu M. Dynapenic abdominal obesity and metabolic risk factors in adults 50 years of age and older. J Aging Health 2012; 24(5): 812-26.
[http://dx.doi.org/10.1177/0898264312440324] [PMID: 22451528]
[20]
Chung JY, Kang HT, Lee DC, Lee HR, Lee YJ. Body composition and its association with cardiometabolic risk factors in the elderly: a focus on sarcopenic obesity. Arch Gerontol Geriatr 2013; 56(1): 270-8.
[http://dx.doi.org/10.1016/j.archger.2012.09.007] [PMID: 23079031]
[21]
Kim TN, Park MS, Lim KI, et al. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf) 2013; 78(4): 525-32.
[http://dx.doi.org/10.1111/j.1365-2265.2012.04433.x] [PMID: 22563924]
[22]
Moon SS. Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009-2010. Endocr J 2014; 61(1): 61-70.
[http://dx.doi.org/10.1507/endocrj.EJ13-0244] [PMID: 24088600]
[23]
Park SH, Park JH, Park HY, et al. Additional role of sarcopenia to waist circumference in predicting the odds of metabolic syndrome. Clin Nutr 2014; 33(4): 668-72.
[http://dx.doi.org/10.1016/j.clnu.2013.08.008] [PMID: 24074549]
[24]
Choudhary NS, Saigal S, Saraf N, et al. Sarcopenic obesity with metabolic syndrome: a newly recognized entity following living donor liver transplantation. Clin Transplant 2015; 29(3): 211-5.
[http://dx.doi.org/10.1111/ctr.12505] [PMID: 25594826]
[25]
Poggiogalle E, Lubrano C, Sergi G, et al. Sarcopenic obesity and metabolic syndrome in adult caucasian subjects. J Nutr Health Aging 2016; 20(9): 958-63.
[http://dx.doi.org/10.1007/s12603-015-0638-1] [PMID: 27791227]
[26]
Ma J, Hwang SJ, McMahon GM, et al. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity (Silver Spring) 2016; 24(2): 526-34.
[http://dx.doi.org/10.1002/oby.21356] [PMID: 26813531]
[27]
Kang SY, Lim GE, Kim YK, et al. Association between sarcopenic obesity and metabolic syndrome in postmenopausal women: A cross-sectional study based on the korean national health and nutritional examination surveys from 2008 to 2011. J Bone Metab 2017; 24(1): 9-14.
[http://dx.doi.org/10.11005/jbm.2017.24.1.9] [PMID: 28326296]
[28]
Aubertin-Leheudre M, Anton S, Beavers DP, et al. Dynapenia and metabolic health in obese and nonobese adults aged 70 years and older: The life study. J Am Med Dir Assoc 2017; 18(4): 312-9.
[http://dx.doi.org/10.1016/j.jamda.2016.10.001] [PMID: 27914851]
[29]
Scott D, Cumming R, Naganathan V, et al. Associations of sarcopenic obesity with the metabolic syndrome and insulin resistance over five years in older men: The Concord Health and Ageing in Men Project. Exp Gerontol 2018; 108: 99-105.
[http://dx.doi.org/10.1016/j.exger.2018.04.006] [PMID: 29649572]
[30]
Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. ACP J Club 1995; 123(3): A12-3.
[PMID: 7582737]
[31]
Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 2007; 7: 16.
[http://dx.doi.org/10.1186/1472-6947-7-16] [PMID: 17573961]
[32]
Aslam S, Emmanuel P. Formulating a researchable question: A critical step for facilitating good clinical research. Indian J Sex Transm Dis AIDS 2010; 31(1): 47-50.
[http://dx.doi.org/10.4103/0253-7184.69003] [PMID: 21808439]
[33]
Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. Endotext. South Dartmouth, MA 2000.
[34]
Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9: 48.
[http://dx.doi.org/10.1186/1741-7015-9-48] [PMID: 21542944]
[35]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[36]
McInnes MDF, Moher D, Thombs BD, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA 2018; 319(4): 388-96.
[http://dx.doi.org/10.1001/jama.2017.19163] [PMID: 29362800]
[37]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6(7)e1000100
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[38]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[39]
Med Calc. Statistical Software version 18113 (Med Calc Software bvba O, Belgium) Available here: https://www.medcalc.org2019.
[40]
Mahajan A. Limitations of cross-sectional studies. Neurol India 2015; 63(6): 1006-7.
[http://dx.doi.org/10.4103/0028-3886.170108] [PMID: 26588658]
[41]
Setia MS. Methodology Series Module 3: Cross-sectional Studies. Indian J Dermatol 2016; 61(3): 261-4.
[http://dx.doi.org/10.4103/0019-5154.182410] [PMID: 27293245]
[42]
Cuthbertson DJ, Bell JA, Ng SY, Kemp GJ, Kivimaki M, Hamer M. Dynapenic obesity and the risk of incident Type 2 diabetes: the English Longitudinal Study of Ageing. Diabet Med 2016; 33(8): 1052-9.
[http://dx.doi.org/10.1111/dme.12991] [PMID: 26479063]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [153 - 162]
Pages: 10
DOI: 10.2174/1573403X16666200214104122
Price: $65

Article Metrics

PDF: 14